ChemoCentryx (CCXI) Stock Price, News & Analysis

Company Overview

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Key Stats

• Today's Range: $51.99 to $51.99
• 50-Day Range: $51.66 to $51.99
• 52-Week Range: $14.95 to $52.00
• Volume: 113 shs
• Average Volume: 1.68 million shs
• Market Capitalization: $3.71 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ChemoCentryx Stock Analysis - MarketRank™

ChemoCentryx scored higher than 15% of companies evaluated by MarketBeat, and ranked 897th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ChemoCentryx.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ChemoCentryx are expected to grow in the coming year, from ($1.81) to ($0.75) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ChemoCentryx is -27.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ChemoCentryx has a P/B Ratio of 12.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CCXI.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ChemoCentryx does not currently pay a dividend.

Dividend Growth

ChemoCentryx does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.2 / 5
• Environmental Score: -1.75

Short Interest

There is no current short interest data available for CCXI.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

MarketBeat Follows

1 people have added ChemoCentryx to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ChemoCentryx insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.30% of the stock of ChemoCentryx is held by insiders.

Percentage Held by Institutions

81.09% of the stock of ChemoCentryx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CCXI Stock Analysis - Frequently Asked Questions

How were ChemoCentryx's earnings last quarter?

ChemoCentryx, Inc. (NASDAQ:CCXI) announced its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.32) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.13. The biopharmaceutical company earned $17.74 million during the quarter, compared to the consensus estimate of $14.70 million. ChemoCentryx had a negative trailing twelve-month return on equity of 48.52% and a negative net margin of 357.01%.

What other stocks do shareholders of ChemoCentryx own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ChemoCentryx investors own include Energy Transfer (ET), Gilead Sciences (GILD), Block (SQ), Exelixis (EXEL), Meta Platforms (META), HubSpot (HUBS) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 11/08/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CCXI
• CUSIP: 16383L10
• CIK: 1340652
• Web: www.chemocentryx.com
• Phone: (650) 210-2900
• Fax: 650-210-2910
• Employees: 178
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-131,760,000.00
• Net Margins: -357.01%
• Pretax Margin: -357.01%
• Return on Equity: -48.52%
• Return on Assets: -30.59%

Debt

• Debt-to-Equity Ratio: 0.02
• Current Ratio: 4.54
• Quick Ratio: 4.47

Sales & Book Value

• Annual Sales: $32.22 million
• Price / Sales: 115.14
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.09 per share
• Price / Book: 12.71

Miscellaneous

• Outstanding Shares: 71,356,000
• Free Float: 65,433,000
• Market Cap: $3.71 billion
• Optionable: Optionable
• Beta: 1.22